Skip to main content
. 2024 Jul 2;11(33):2309885. doi: 10.1002/advs.202309885

Figure 6.

Figure 6

Synergistic therapeutic effect of anti‐HIF1 combined with PD‐1 blockade, a) Graphic illustration of syngeneic models established from 4T1 and B16F10 cells for combinatorial treatment. b,c) Kaplan–Meier survival analysis of syngeneic 4T1 mice model treated with scramble or HIF1 LNA (treated with EZN‐2968), immune checkpoint blocks (ICB) alone or in combination (n = 8, 8, 8, 11 animals) (b), log rank test. (c) Kaplan–Meier survival analysis of syngeneic B16F10 mice model treated with scramble or HIF1 LNA, immune checkpoint blocks (ICB) alone or in combination (n = 8, 8, 8, 10 animals). d,e) Tumor volumes of syngeneic 4T1 (d) and B16F10 (e) mice model treated with scramble or HIF1 LNA, ICB alone or in combination. f,g) Flow cytometry analyzing the expression of PD‐1 and Lag3 in ALCAM high and ALCAM low macrophages from human (f) and mouse tumor tissues (g). h,i) CellTrace dilution assay to assess the division of CD8 T cell co‐cultured with ALCAM high and ALCAM low macrophages from human (h) and mouse tumor tissues (i). A two‐sided unpaired t‐test was used to assess statistical significance in (f–i).